SSG
ANIP icon

Summit Securities Group’s ANI Pharmaceuticals ANIP Stock Holding History

Summit Securities Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,531
Closed -$140K – 450
2023
Q4 		$140K Buy
+2,531
New +$139K 0.01% 291
2013
Q3 		– Sell
-2
Closed – – 419
2013
Q2 		$0 Buy
+2
New +$14 ﹤0.01% 600

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Securities Group's ANIP Position: Q1 2024 in Review

Summit Securities Group sold out of ANI Pharmaceuticals (ANIP) in Q1 2024, closing a stake of 2,531 shares — an estimated $140K sold.

Summit Securities Group first reported a position in ANIP in Q2 2013 and held it in 2 quarters. The position peaked at $140K in Q4 2023. 199 funds tracked by Wall St. Rank hold ANIP as of Q1 2024.

  • Summit Securities Group reported no remaining ANI Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Summit Securities Group sold 2,531 ANI Pharmaceuticals shares in Q1 2024, an estimated $140K.
  • Summit Securities Group first reported a position in ANI Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Summit Securities Group's ANI Pharmaceuticals position peaked at $140K in Q4 2023.
  • 199 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2024.

Based on Summit Securities Group's 13F filing for Q1 2024, filed 13 May 2024.